14.936 articles found

Prodromal Lewy body disorder features in REM sleep behavior disorder with biomarker-defined synucleinopathy

Weintraub D, York MK, Dobkin R, Nair AR, Kurth R, Lafontant D, Caspell-Garcia C, Alcalay RN, Brown EG, Chahine LM, Coffey C, Foroud T, Galasko D, Kieburtz K, Marek K, Merchant K, Mollenhauer B, Poston KL, Siderowf A, Simonet C, Simuni T, Tanner CM, Tropea TF, Videnovic A, Parkinson’s Progression Markers Initiative.

· 2026-01-01

DOI: 10.64898/2025.12.24.25342976

Morphological variation and genetic diversity of breadfruit [Artocarpus altilis (Parkinson) Fosberg] in Vanuatu

Kaoh J, Labouisse JP, Bulememe B, Rivallan R, Garavito A, Lebot V.

Genetic resources and crop evolution. · 2026-01-01

Amyloid, p‐tau, neurofilament light, and α‐synuclein cerebrospinal fluid biomarkers across Alzheimer's disease, dementia with Lewy bodies, and Parkinson's disease

Rizzo M, Teunissen C, Zetterberg H, Blennow K, Kollmorgen G, Krüger R, Fernandes S, Aarsland D, Borejko O, Hu M, Chokoshvili D, Vijverberg J, Lemstra A, Tijms B, Petzold G, Brockmann K, Gasser T, Frisoni G, Hort J, Nedelska Z, Hopøy A, Fladby T, Jessen F, Düzel E, Spottke A, Höglinger G, Mutel S, Chevalier C, Krishnan R, Visser P, Vos S.

Alzheimer's & dementia (Amsterdam, Netherlands) · 2026-01-01

Studies on topological maturation of α-synuclein fibrils in Parkinson's disease: Insights from persistent homology and SARS-CoV-2 acceleration of aggregation

Jalapally P, Emani L, Izudheen S, Jagannatha Rao K.

Journal of Alzheimer's disease reports · 2026-01-01

ProSAAS overexpression arrests progression of motor deficits in a rat alpha-synuclein model of Parkinson’s disease

Shu Z, Lam H, Videlock E, Lindberg I, Maidment N.

Translational neurodegeneration · 2026-01-01

Comprehensive genetic screening of the South African Parkinson's disease study collection using the NeuroBooster array

Step K, Madula L, Kuznetsov N, Maasdorp E, Carr J, van Coller R, Möller M, Mata I, Bardien S.

Clinical parkinsonism & related disorders · 2026-01-01

LRRK2 kinase activity restricts NRF2-dependent mitochondrial protection in microglia.

Weindel CG, Coleman AK, Ellzey LM, Kumar S, Chaisson SL, Davis JR, Patrick KL, Watson RO.

J Immunol · 2026-01-01

DOI: 10.1093/jimmun/vkaf215PMID: 40906893

α-Synuclein signatures mark Parkinson disease subtypes.

Wood H.

Nat Rev Neurol · 2026-01-01

DOI: 10.1038/s41582-025-01176-6PMID: 41361101

Genetic Engineering and Encapsulation Strategies for <i>Lacticaseibacillus rhamnosus</i> Enhanced Functionalities and Delivery: Recent Advances and Future Approaches.

Grigore-Gurgu L, Leuștean-Bucur FI, Bahrim GE.

Foods · 2026-01-01

DOI: 10.3390/foods15010123PMID: 41517189

α-Synuclein Real-Time Quaking-Induced Conversion Assay as a Biomarker for Parkinson's Disease: Clinical Implications and Perspectives.

Yu JK, Lee YK, Yea DA, Kim YE.

J Clin Neurol · 2026-01-01

DOI: 10.3988/jcn.2025.0235PMID: 41517811

Targeting α-Synuclein: Current Strategies and Emerging Therapies for Synucleinopathies.

Bala VC, Singh MK, Kumar A, Tiwari SK, Gupta AK, Chawla R, Kumar S.

Protein Pept Lett · 2026-01-01

DOI: 10.2174/0109298665429866260217115717PMID: 42116584

Optogenetics for therapeutic use in the brain, eye, and ear.

Ng BWJ, Maclaren RE, Cehajic-Kapetanovic J.

Handb Clin Neurol · 2026-01-01

DOI: 10.1016/b978-0-443-22212-2.00018-5PMID: 42217988